Current review and clinical management of patients with primary HIV-1 infection: Limits and perspectives

Biomedicine and Pharmacotherapy

Volumn 55, Issue 6, 2001, Pages 301-307

  Hermans, P ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cellular immune response; HAART; Primary HIV infection (PHI); Review; Structured treatment interruption (STI); Vaccines

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DIDANOSINE; INTERLEUKIN 2; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VACCINE; ZIDOVUDINE;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFECT; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0034961244     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(01)00064-6     Document Type: Article

References (36)

1. Declining morbidity and mortality among patients with advanced HIV infection
2. Intermittent interruptions of antiretroviral therapy in chronically HIV-infected patients do not induce immune control of HIV
3. Rapid activation of lymph nodes upon interrupting HAART in HIV-infected patients after prolonged viral suppression
4. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
5. Boosting of HIV-1-specific cellular immune responses in chronically infected persons after treatment interruption
6. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection
7. CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART
8. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
9. Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection
10. A controlled trial of zidovudine in primary human immunodeficiency virus infection
11. Primary HIV infection: Follow-up of patients initially randomized to zidovudine or placebo
12. Reduced viremia and increased CD4/CD8 ratio in patients with primary HIV infection treated with AZT-ddI
13. Combined therapy with zidovudine and L-697,661 in primary HIV infection
14. Effects of a combination of zidovudine, didanosine and lamivudine on primary HIV-1 infection
15. Intermittent therapy after d4T/ddI/NVP + /- hydroxyurea initiated during PHI
16. The qualitative nature of the primary immune response to HIV infection is a prognostic factor of disease progression independent of the initial level of plasma viremia
17. Potent antiretroviral therapy of primary HIV-1 infection: Partial normalizeation of T lymphocytes subsets and limited reduction of HIV DNA despite clearance of plasma viremia
18. Increase in breadth and frequency of CTL responses after structured therapy interruptions in individuals treated with HAART during acute HIV-1 infection
19. Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection
20. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection
21. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
22. Preliminary results: Quadruple HAART (ZDV/3TC/Abacavir/ Amprenavir) initiated during PHI is associated with a sharp viremia decrease and increase in CD4+ response
23. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
24. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
25. Early treatment of HIV-1 infection
26. Antiretroviral resistance during successful therapy of HIV type 1 infection
27. Control of HIV despite the discontinuation of antiretroviral therapy
28. Immune control of HIV-1 after early treatment of acute infection
29. Discontinuation of therapy after treatment for primary HIV infection
30. Long term evaluation of triple nucleoside therapy administered from primary HIV-1 infection
31. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
32. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
33. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
34. Activity of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection
35. Primary infection with zidovudine-resistant HIV
36. Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy